Advertisement
Screener

PRECIGEN, INC. (PGEN) Operating Expenses

2.8 / 5 stars · 68/120 Roast Me

PRECIGEN, INC. Operating Expenses

PRECIGEN, INC. (PGEN) reported Operating Expenses of $32.34 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.

Financial Statements › Expense Statement › Operating Expenses

us-gaap:OperatingExpenses · last filed 2026-08-04

  • PRECIGEN, INC. operating expenses for the quarter ending 2026-06-30 was $32.34M, a 0.87% decline year-over-year.
  • PRECIGEN, INC. operating expenses for the quarter ending 2026-03-31 was $29.25M, a 22.18% increase year-over-year.
  • PRECIGEN, INC. operating expenses for the quarter ending 2025-06-30 was $32.62M.
  • PRECIGEN, INC. operating expenses for the quarter ending 2025-03-31 was $23.94M.
  • PRECIGEN, INC. operating expenses for fiscal 2025 was $120.19M, a 13.50% decline from fiscal 2024.
  • PRECIGEN, INC. operating expenses for fiscal 2024 was $138.95M, a 31.11% increase from fiscal 2023.
  • PRECIGEN, INC. operating expenses for fiscal 2023 was $105.98M.
  • PRECIGEN, INC. operating expenses for fiscal 2018 was $666.18M, a 80.60% increase from fiscal 2017.
Period endOperating Expenses 3 monthOperating Expenses 3 month as first filedOperating Expenses 6 monthOperating Expenses 6 month as first filedOperating Expenses 9 monthOperating Expenses 9 month as first filedOperating Expenses 12 month
2026-06-30$32.34M
10-Q · filed 2026-08-04
$61.58M
10-Q · filed 2026-08-04
2026-03-31$29.25M
10-Q · filed 2026-05-13
2025-12-31$120.19M
10-K · filed 2026-03-25
2025-06-30$32.62M
10-Q · filed 2026-08-04
$56.56M
10-Q · filed 2026-08-04
2025-03-31$23.94M
10-Q · filed 2026-05-13
2024-12-31$138.95M
10-K · filed 2026-03-25
2023-12-31$105.98M
10-K · filed 2026-03-25
2019-09-30$71.66M
10-Q · filed 2019-11-12
$145.06M
derived: sum of 2 quarters · filed 2019-11-12
$227.09M
10-Q · filed 2019-11-12
$607.16M
derived: sum of 4 quarters · filed 2019-11-12
2019-06-30$73.39M
10-Q · filed 2019-08-09
$155.43M
10-Q · filed 2019-08-09
$535.50M
derived: sum of 3 quarters · filed 2019-08-09
$634.42M
derived: sum of 4 quarters · filed 2019-11-12
2019-03-31$82.04M
10-Q · filed 2019-05-09
$462.11M
derived: sum of 2 quarters · filed 2019-05-09
$561.02M
derived: sum of 3 quarters · filed 2019-11-12
$656.03M
derived: sum of 4 quarters · filed 2019-11-12
2018-12-31$380.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$478.99M
derived: sum of 2 quarters · filed 2019-11-12
$574.00M
derived: sum of 3 quarters · filed 2019-11-12
$666.18M
10-K · filed 2019-03-01
2018-09-30$98.92M
10-Q · filed 2019-11-12
$193.93M
derived: sum of 2 quarters · filed 2019-11-12
$286.12M
10-Q · filed 2019-11-12
$389.77M
derived: sum of 4 quarters · filed 2019-11-12
2018-06-30$95.01M
10-Q · filed 2019-08-09
$187.20M
10-Q · filed 2019-08-09
$290.85M
derived: sum of 3 quarters · filed 2019-08-09
$381.61M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31$92.32M
10-Q · filed 2019-05-09
$195.84M
derived: sum of 2 quarters · filed 2019-05-09
$286.60M
derived: sum of 3 quarters · filed 2019-05-09
$376.30M
derived: sum of 4 quarters · filed 2019-05-09
2017-12-31$103.52M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$194.28M
derived: sum of 2 quarters · filed 2019-03-01
$283.99M
derived: sum of 3 quarters · filed 2019-03-01
$368.87M
10-K · filed 2019-03-01
2017-09-30$90.76M
10-Q · filed 2018-11-08
$180.47M
derived: sum of 2 quarters · filed 2018-11-08
$265.35M
10-Q · filed 2018-11-08
$344.19M
derived: sum of 4 quarters · filed 2019-03-01
2017-06-30$89.70M
10-Q · filed 2018-08-13
$174.59M
10-Q · filed 2018-08-13
$253.42M
derived: sum of 3 quarters · filed 2019-03-01
$331.23M
derived: sum of 4 quarters · filed 2019-03-01
2017-03-31$85.13M
10-Q/A · filed 2018-08-13
$163.72M
derived: sum of 2 quarters · filed 2019-03-01
$241.53M
derived: sum of 3 quarters · filed 2019-03-01
$317.25M
derived: sum of 4 quarters · filed 2019-03-01
2016-12-31$78.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-01
$156.40M
derived: sum of 2 quarters · filed 2019-03-01
$232.12M
derived: sum of 3 quarters · filed 2019-03-01
$316.09M
10-K · filed 2019-03-01
2016-09-30$77.81M
10-Q · filed 2017-11-09
$153.53M
derived: sum of 2 quarters · filed 2017-11-09
$237.50M
10-Q · filed 2017-11-09
$313.39M
derived: sum of 4 quarters · filed 2018-03-01
2016-06-30$75.72M
10-Q · filed 2017-08-09
$159.69M
10-Q · filed 2017-08-09
$235.59M
derived: sum of 3 quarters · filed 2018-03-01
$296.87M
derived: sum of 4 quarters · filed 2018-03-01
2016-03-31$83.97M
10-Q · filed 2017-05-10
$159.86M
derived: sum of 2 quarters · filed 2018-03-01
$221.15M
derived: sum of 3 quarters · filed 2018-03-01
$283.47M
derived: sum of 4 quarters · filed 2018-03-01
2015-12-31$75.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01
$137.18M
derived: sum of 2 quarters · filed 2018-03-01
$199.50M
derived: sum of 3 quarters · filed 2018-03-01
$320.47M
10-K · filed 2018-03-01
2015-09-30$61.28M
10-Q · filed 2016-11-09
$123.60M
derived: sum of 2 quarters · filed 2016-11-09
$244.58M
10-Q · filed 2016-11-09
$294.63M
derived: sum of 4 quarters · filed 2017-03-01
2015-06-30$62.32M
10-Q · filed 2016-08-09
$183.29M
10-Q · filed 2016-08-09
$233.35M
derived: sum of 3 quarters · filed 2017-03-01
$269.59M
derived: sum of 4 quarters · filed 2017-03-01
2015-03-31$120.97M
10-Q · filed 2016-05-10
$171.03M
derived: sum of 2 quarters · filed 2017-03-01
$207.27M
derived: sum of 3 quarters · filed 2017-03-01
$237.14M
derived: sum of 4 quarters · filed 2017-03-01
2014-12-31$50.05M
derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01
$86.30M
derived: sum of 2 quarters · filed 2017-03-01
$116.17M
derived: sum of 3 quarters · filed 2017-03-01
$141.89M
10-K · filed 2017-03-01
2014-09-30$36.24M
10-Q · filed 2015-11-09
$66.11M
derived: sum of 2 quarters · filed 2015-11-09
$91.84M
10-Q · filed 2015-11-09
$116.71M
derived: sum of 4 quarters · filed 2016-02-29
2014-06-30$29.87M
10-Q · filed 2015-08-10
$55.59M
10-Q · filed 2015-08-10
$80.46M
derived: sum of 3 quarters · filed 2016-02-29
$98.63M
derived: sum of 4 quarters · filed 2016-02-29
2014-03-31$25.73M
10-Q · filed 2015-05-11
$50.59M
derived: sum of 2 quarters · filed 2016-02-29
$68.77M
derived: sum of 3 quarters · filed 2016-02-29
$89.71M
derived: sum of 4 quarters · filed 2016-02-29
2013-12-31$24.87M
derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29
$43.04M
derived: sum of 2 quarters · filed 2016-02-29
$63.98M
derived: sum of 3 quarters · filed 2016-02-29
$81.78M
10-K · filed 2016-02-29
2013-09-30$18.08M
10-Q · filed 2014-11-13
$39.11M
derived: sum of 2 quarters · filed 2014-08-14
$56.91M
10-Q · filed 2014-11-13
$57.19M
10-Q · filed 2013-11-07
$75.81M
derived: sum of 4 quarters · filed 2015-03-02
2013-06-30$20.94M
10-Q · filed 2014-08-14
$21.04M
10-Q/A · filed 2013-10-21
$38.84M
10-Q · filed 2014-08-14
$39.02M
10-Q/A · filed 2013-10-21
$57.64M
derived: sum of 3 quarters · filed 2015-03-02
$77.05M
derived: sum of 4 quarters · filed 2015-03-02
2013-03-31$17.89M
10-Q · filed 2014-05-09
$36.70M
derived: sum of 2 quarters · filed 2015-03-02
$56.11M
derived: sum of 3 quarters · filed 2015-03-02
$80.08M
derived: sum of 4 quarters · filed 2015-03-02
2012-12-31$18.81M
derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02
$38.22M
derived: sum of 2 quarters · filed 2015-03-02
$62.19M
derived: sum of 3 quarters · filed 2015-03-02
$88.93M
10-K · filed 2015-03-02
2012-09-30$19.41M
10-Q · filed 2013-11-07
$43.38M
derived: sum of 2 quarters · filed 2013-11-07
$70.12M
10-Q · filed 2013-11-07
2012-06-30$23.97M
10-Q/A · filed 2013-10-21
$50.71M
10-Q/A · filed 2013-10-21
2011-12-31$90.44M
10-K · filed 2014-03-31

Similar stocks

Stock NameCountryMarket CapPE Ratio
NewAmsterdam Pharma Co N.V. (NAMS)$2.719B-15.37
MBX Biosciences, Inc. (MBX)United States$2.664B-25.36
Disc Medicine, Inc. (IRON)United States$2.553B-11.40
Immunome Inc. (IMNM)United States$2.538B-9.45
SUPERNUS PHARMACEUTICALS, INC. (SUPN)United States$2.517B-24.63
Nurix Therapeutics, Inc. (NRIX)United States$2.457B-5.39
Dyne Therapeutics, Inc. (DYN)United States$3.084B-7.09
SELLAS Life Sciences Group, Inc. (SLS)United States$2.420B-91.87
uniQure N.V. (QURE)$2.416B-4.93
Vera Therapeutics, Inc. (VERA)United States$2.402B-7.67